Adaptimmune Therapeutics (Adaptimmune Therapeutics) Change In Receivables : $-1.29 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics Change In Receivables?

Adaptimmune Therapeutics's change in receivables for the quarter that ended in Dec. 2023 was $-0.58 Mil. It means Adaptimmune Therapeutics's Accounts Receivable increased by $0.58 Mil from Sep. 2023 to Dec. 2023 .

Adaptimmune Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $-1.29 Mil. It means Adaptimmune Therapeutics's Accounts Receivable increased by $1.29 Mil from Dec. 2022 to Dec. 2023 .

Adaptimmune Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.82 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Adaptimmune Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 324.31.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Adaptimmune Therapeutics's liquidation value for the three months ended in Dec. 2023 was $-95.55 Mil.

Adaptimmune Therapeutics Change In Receivables Historical Data

The historical data trend for Adaptimmune Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics Change In Receivables Chart

Adaptimmune Therapeutics Annual Data

Trend

Jun14

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-1.44

1.75

-19.36

-9.81

-1.29

Adaptimmune Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															19.97	3.68	-1.71	-2.68	-0.58

Adaptimmune Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.29 Mil.

Adaptimmune Therapeutics (NAS:ADAP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Adaptimmune Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.821	/	0.231	*	91
=	324.31

2. In Ben Graham's calculation of liquidation value, Adaptimmune Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Adaptimmune Therapeutics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	146.938	-	243.103	+	0.75 * 0.821	+	0.5 * 0
=	-95.55

Adaptimmune Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics (Adaptimmune Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (NAS:ADAP) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

473A:Germany

Address

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.adaptimmune.com

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

Executives

Elliot Norry	officer: Chief Medical Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Bertrand William C Jr	officer: Chief Operating Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
John Lunger	officer: Chief Patient Supply Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Adrian Rawcliffe	officer: Chief Financial Officer	440 SOUTH BROAD STREET, UNIT 1906, PHILADELPHIA PA 19146
Kristen Hege	director	500 FORBES BLVD, SOUTH SAN FRANCISCO CA 94070
Garry E Menzel	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Priti Hegde	director	TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Andrew R Allen	director	2525 28TH STREET, SUITE 200, BOULDER CO 80301
Cintia Piccina	officer: Chief Commercial Officer	60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Gavin Wood	officer: Chief Financial Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Joanna Elizabeth Brewer	officer: Chief Scientific Officer	60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Helena Katrina Tayton-martin	officer: Chief Operating Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James Noble	director, officer: Chief Executive Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX